Kiora Pharmaceuticals, Inc. Overview
Pro stress-test →Kiora Pharmaceuticals is a clinical-stage biopharmaceutical company developing advanced treatments for retinal disease. The company targets critical pathways underlying eye disease with innovative small molecules to preserve, slow, or restore vision loss. The company is advancing two Phase 2 clinical trials with potential to address significant unmet needs in inherited and inflammatory retinal conditions.
Strategic Profile
Pro stress-test →The lead product KIO-301 is a potential vision-restoring small molecule in Phase 2 clinical trials for retinitis pigmentosa, choroideremia, and Stargardt disease. The company entered into an option agreement with Senju Pharmaceutical for development and commercialization in Asia with a potential deal value of up to $110 million plus royalties (August 2025). Kiora has a strategic development and commercialization agreement with Théa Open Innovation for KIO-301.
Competitive Landscape
Pro stress-test →Kiora was incorporated in 1998 and was formerly known as Eyegate Pharmaceuticals before rebranding in November 2021. The company operates in a specialized niche—inherited and inflammatory retinal diseases—with limited direct competition for molecular photoswitches. Major ophthalmic competitors (Novartis, Allergan, Bausch Health) operate in broader eye care; Kiora's photoswitch approach is novel but clinical-stage success is essential. Partnership validation from Senju and Théa signals confidence in scientific approach.
Industry Context
Kiora Pharmaceuticals, Inc. operates in Biopharmaceutical / Ophthalmology / Retinal Disease.
Key facts
Founded: 1998 · Headquarters: Encinitas, California, US